Poseida Therapeutics Presents High-Fidelity Genome Editing System for Production of Allogeneic “Universal Donor” CAR-T Cells at American Society of Clinical Oncology Annual Meeting

Poseida Therapeutics, Inc. (“Poseida”), a San Diego-based company translating best-in-class gene editing technologies into lifesaving therapeutics, today announced preclinical data demonstrating the use of the company’s proprietary high-fidelity genome editing system, NextGEN™ CRISPR, for production of allogeneic “universal donor” chimeric antigen receptor  T-cells (CAR-T). In a study presented today at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting, the world’s premier oncology event, researchers at Poseida used its proprietary gene editing tools to create a universal donor CAR-T cell therapy that circumvents rejection by the body and avoids premature CAR-T cell exhaustion – two key challenges that have hindered the development of an “off the shelf” CAR-T cell therapy.